Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP
Corbus Pharmaceuticals — Investor Presentation (October 2026)
62 slides from Corbus Pharmaceuticals's investor presentation, Oct 15, 2026
Slide 1: Connecting Innovation to Purpose Corporate Presentation
Connecting Innovation to Purpose Corporate Presentation October 15, 2026 Exhibit 99.1
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act of 1995, as amended, including those relating to the Company’s trial resul
Slide 3: Differentiated portfolio in Oncology and Obesity Overview
Peripherally restricted CB1 inverse agonist for obesity Competitive 5% placebo adjusted weight loss in Phase 1b at 12 weeks Favorable emerging safety and tolerability profile Phase 2 monotherapy study expected to start 1H 2027 > 1 billion people worldwide living with obesity OBESITY Differentiated p
Slide 4: Focused and diversified pipeline
Focused and diversified pipeline Therapy Mechanism of Action Indication (rights) Pre-Clinical Phase 1 Phase 2 Phase 3 Milestones CRB-701 Nectin-4 ADC positive solid tumors 2L OPSCC (US + Europe) First patient dosed in TEMPO-1 in Sept. 2026 1L OPSCC (US + Europe) Topline ORR data expected in Q1 2027
Slide 5: Senior Management Team
Senior Management Team Yuval Cohen, PhD Chief Executive Officer, Director Corbus co-founder and Chief Executive Officer since 2014. Previously the President and co-founder of Celsus Therapeutics from 2005. Sean Moran, CPA, MBA Chief Financial Officer Corbus co-founder and Chief Financial Officer since
Slide 6: Board of Directors
Board of Directors Winston Kung, MBA Director More than 20 years of senior financial, business development and investment banking experience; currently CFO of ArriVent. (NASDAQ: AVBP) Yuval Cohen, PhD Chief Executive Officer, Director Corbus co-founder and Chief Executive Officer since 2014. Previousl
Slide 7: Anticipated corporate milestones
Anticipated corporate milestones Commence registrational study in 2L OPSCC CRB-701 + pembrolizumab in 1L OPSCC data Interim ORR readout in 2L OPSCC Potential BLA filing for 2L OPSCC Sept 2026 Q1 2027 1H 2028 2H 2028 CRB-701 Additional Phase 1b data at ObesityWeek® 2026 Initiate Phase 2 monotherapy s
Slide 8: CRB-701 Next-Generation Nectin-4 ADC targeting OPSCC and cervical cancers
CRB-701 Next-Generation Nectin-4 ADC targeting oropharyngeal (OPSCC) and cervical cancers
Slide 9: CRB-701: Reimagining the next-generation Nectin-4 ADC
CRB-701 DAY 1 1.25 mg/kg DAY 8 1.25 mg/kg DAY 15 1.25 mg/kg DAY 22 dose holiday DAY 28 DAY 1 CRB-701 DAY 8 dose holiday DAY 15 dose holiday DAY 22 CRB-701: Reimagining the next-generation Nectin-4 ADC Source(s): Modified image from Corbus data on file; Corbus data on file; PADCEV® FDA label MMAE = M
Slide 10: CRB-701-01 Study design (U.S. and Europe)
CRB-701-01 Study design (U.S. and Europe) cORR, confirmed objective response rate; DLT, dose-limiting toxicity; DoR, duration of response; MMAE, monomethyl auristatin E; PFS, progression-free survival; Q3W, every 3 weeks Dose Optimization (Project Optimus): HNSCC & cervical Dose escalation Dose esca
Slide 11: ASCO 2026: Key characteristics & tumor types
Baseline Characteristic HNSCC Cervical Median age (range) 62 (24–78) 54 (32–78) Sex (M/F) 89.3% / 10.7% NA / 100% ECOG PS** 0, 1, 2 47%, 52%, 1% 44%, 56%, 0% Weight in kg mean (range) 75.2 (41.3–132.8) 64.3 (39.0–99.0) Prior therapies median (range) 3 (1–9) 3 (1–7) Enrolled Tumor Types Safety Popula
Slide 12: ASCO 2026: Study safety population TRAEs
TRAE n=317 (%) Grade 3 19.2% Grade 4 0.9% Grade 5 None PERIPHERAL NEUROPATHY (broad terms*) Grade 1 and 2 7.3% Grade >3 None SKIN (most common, excluding alopecia) Pruritus 14.2% Dry skin 13.2% Rash 5.7% Grade 3 - rash 0.3% Grade ≥4 None OCULAR Overall 66.2% Grade 3 12.6% Grade 4 0.3%** DISCONTINUAT
Slide 13: ASCO 2026: Safety Summary (TRAEs, N=317)
Low rates of skin adverse events Eye toxicities manageable with prophylaxis and dose modification Potentially best-in-class for peripheral neuropathy ASCO 2026: Safety Summary (TRAEs, N=317) Source(s): ASCO April 1, 2026 data cut; *Standardized MedDRA Category Search; **general rash; TRAEs = Treatme
Slide 14: CRB-701 in 2L+ Oropharyngeal Head and Neck Cancer (OPSCC)
CRB-701 in 2L+ Oropharyngeal Head and Neck Cancer (OPSCC)
Slide 15: What is Oropharyngeal Squamous Cell Carcinoma (OPSCC)?
Associated with higher Nectin-4 expression2 HPV+ selectivity seen with PADCEV® in 1L HNSCC3 HPV+ tumors (80–90% of OPSCC)1 What is Oropharyngeal Squamous Cell Carcinoma (OPSCC)? Source(s): Image Corbus licensed ChatGPT account; 1. Ozdogan et al 2025; 2. Sander et al, 2022; 3. Swiecicki et al 2026. D
Slide 16: OPSCC is on the rise in the U.S.
OPSCC is on the rise in the U.S. as prevalence of HPV+ in HNSCC is increasing: 11% 57% over last 30 years Source(s): Data generated by Greenhill: (1) Portugal et al., 1997; (2) Dahlstrom et al., 2003; (3) Chaturvedi et al., 2008; (4) Cole et al., 2012; (5) Bauml et al., 2017; (6) Wu et al., 2021;
Slide 17: OPSCC growing in HNSCC: HPV+ incidence growing while HPV- decreasing
↑ HPV+ Pathway ↓ HPV- Pathway Two Opposing Drivers ↑ HPV+ HNSCC (younger, non-smoking patients) ↓ HPV− HNSCC (older, heavy smoker/drinker patients) OPSCC growing in HNSCC: HPV+ incidence is growing while HPV- is decreasing Source(s): Data generated by Greenhill; (1) Chaturvedi, A. K. et al., 2011; (
Slide 18: Summary of OPSCC U.S. Epidemiology and Treatment Eligibility
Summary of OPSCC U.S. Epidemiology and Treatment Eligibility Source(s): *LifeSci Consulting Qualitative Market Research ; **American Cancer Society Statistics 2026 for Oral Cavity and Oropharyngeal Cancer: 13,150 deaths and the Company estimates 7,000 attributable to OPSCC Total Prevalence: ∼114,000
Slide 19: ASCO 2026: Key characteristics in HNSCC and subsets
Enrolled Tumor Types HNSCC All-comers ( n=75 ) OPSCC Subset ( n=41 ) Other HNSCC anatomical subsets ( n=34 ) Median age (range) 62 (24–78) 62.0 (36–77) 62 (24–78) Sex (M/F) 89.3% / 10.7% 90.2% / 9.8% 88.2% / 11.8% ECOG PS 0, 1, 2 47%, 52%, 1% 58.5%, 41.5%, 0% 32.4%, 64.7%, 2.9% Weight in kg mean (ra
Slide 20: OPSCC associated with HPV positivity and higher nectin-4 levels
Nectin-4 H score>150 1 in 3 1 in 10 Nectin-4 H score>175 1 in 4 1 in 12 Nectin-4 H score>200 1 in 6 1 in 30 HNSCC ASCO 2026: OPSCC associated with HPV positivity in our study (as expected) and higher nectin-4 levels Source(s): ASCO April 1, 2026 data cut. BASELINE HPV+ HPV- Unknown
Slide 21: CRB-701 confirmed responses favor OPSCC
2.7 mg/kg 3.6 mg/kg cORR 20.0% (4/20) 42.9% (9/21) DCR 90.0% (18/20) 85.7% (18/21) 2.7 mg/kg 3.6 mg/kg cORR 7.1% (1/14) 0.0% (0/16) DCR 57.1% (8/14) 62.5% (10/16) ASCO 2026: CRB-701 confirmed responses favor OPSCC Source(s): ASCO April 1, 2026 data cut; Patients are summarized on the treatment and d
Slide 22: CRB-701 had longer durability in OPSCC
Subject Details WEEKS ON TREATMENT 3.6 mg/kg 2.7 mg/kg ASCO 2026: CRB-701 had longer durability in OPSCC Source(s): ASCO April 1,2026 data cut; HNSCC = Head & Neck Squamous Cell Carcinoma; OPSCC = Oropharyngeal Squamous Cell Carcinoma; DoR = Duration of Response; PFS = Progression-Free Survival HNSC
Slide 23: Efficacy summary at 3.6 mg/kg Q3W
3.6 mg/kg Q3W OPSCC ( n=21 ) Non-OPSCC ( n=16 ) cORR 42.9% 0% DCR 85.7% 62.5% DoR (months) 6.3 NA PFS (months) 5.6 2.7 % responders HPV+ 89% (8 out of 9) NA ASCO 2026: Efficacy summary at 3.6 mg/kg Q3W OPSCC is indication of choice EFFICACY Source(s): ASCO April 2026 data cut; OPSCC = Oropharyngeal
Slide 24: Contextualizing monotherapy CRB-701 and petosemtamab in 2L HPV+/OPSCC
RP2D OPSCC population Petosemtamab* (n=15)*** CRB-701** (n=21) Dosing regimen 1500 mg Q2W 3.6 mg/kg Q3W Efficacy (cORR) 13% (2/15) in OPSCC HPV+ only 50% (8/16) in OPSCC HPV+ only 43% (9/21) in OPSCC all types Median DoR (months) 6.2 in HNSCC 6.3 in OPSCC (ongoing) PFS (months) 4.9 in HNSCC 5.6 in
Slide 25: TEMPO-1 Registrational Study
TEMPO-1 Registrational Study STUDY DESIGN ELIGIBLE POPULATION Recurrent OPSCC Prior Platinum & Anti–PD-(L)1 RANDOMIZED 3.6 mg/kg dose 1:1 CRB-701 Monotherapy N≈125 INVESTIGATOR’S CHOICE Monotherapy N≈125 ADAPTIVE FEATURE Interim Analysis → Sample Size Re-Estimation Seamless Phase 2 → Phase 3 Transit
Slide 26: 1L OPSCC potential: precedent of Padcev + Keytruda
Padcev® + Keytruda® cORR All 39% (16/41) HPV+ 82% (9/11) HPV- 23% (7/30) Notes: TRAEs ≥ Grade 3: 41% Peripheral neuropathy: 32% 1L OPSCC potential: the precedent of Padcev® + Keytruda® in 1L Source(s): 1. Swiecicki et al 2026 2. Van Herpen ASCO 2025 3.Hanna et al 2026; cORR = confirmed Objective Res
Slide 27: Padcev added to 2026 NCCN guidelines for HNSCC
Padcev® added to the 2026 NCCN treatment guidelines* for HNSCC * National Guidelines Version 2.2026 Head and Neck Cancer –Page 119 ** Swiecicki et al 2024 Swiecicki et al 2024** Padcev® 2L+ cORR All-comers 24% (11/46) Notes: Demographics: 65% U.S. & 35% Japan No breakdown by p16 TRAEs ≥ Grade 3: 35%
Slide 28: Cervical Cancer: Acute unmet need in 2L
Cervical Cancer Acute unmet need in 2L in poorly addressed market
Slide 29: Cervical Cancer: Commercial Opportunity for CRB-701
Cervical Cancer: Commercial Opportunity for CRB-701 Source(s): 1. https://www.cancer.org/cancer/types/cervical-cancer/about/key-statistics.html , 2. Study reveals why cervical cancer screening rates are declining, which populations are most affected - UTHealth Houston School of Public Health , 3. HP
Slide 30: Few options for 2L cervical cancer
FULL APPROVAL Few options for 2L cervical cancer Source(s): Vergote et al 2024 1L 2L Tisotumab vedotin Single-Agent Chemo Carbo + Paclitaxel +/- Beva +/- Pembrolizumab ACCELERATED APPROVAL 2021 2024 CERVICAL CANCER
Slide 31: Tivdak demonstrates a commercial potential that could be further improved
Efficacy**** ORR 17.8% PFS 4.2 months OS 11.5 months Adverse event profile**** Ocular (Black Box) 55% (all grades) Peripheral neuropathy 39% (all grades) Bleeding 51% (all grades) Rash 25% (all grades) USA numbers Value R/M patients receiving 2L treatment 38%* Annual price (WAC) $466,208** Annualize
Slide 32: Key characteristics & tumor types: Cervical
Enrolled Tumor Types Safety Population Efficacy Evaluable Population Cervical 72 70 Baseline Characteristic Cervical Median age (range) 54 (32, 78) Sex (M/F) NA/100% ECOG PS 0, 1, 2 44.4%, 55.6%, 0% Weight in kg mean (range) 64.3 (39.0–99.0) Prior therapies median (range) 3 (1–7) ASCO 2026: Key char
Slide 33: CRB-701 ASCO 2026: Waterfall plot (N=70)
CRB-701 ASCO 2026: Waterfall plot (N=70) Source(s): ASCO April 2026 data cut; Patients are summarized on the treatment and dose level assigned at enrollment/randomization. Best Overall Response is displayed at the end of each bar. cCR = confirmed Complete response; cORR = confirmed Objective Respons
Slide 34: CRB-701 ASCO 2026: Swimmer plots (N=70)
Subject Details WEEKS ON TREATMENT 3.6 mg/kg 2.7 mg/kg CRB-701 ASCO 2026: Swimmer plots (N=70) Source(s): ASCO April 1, 2026 data cut; DoR = Duration of Response; PFS = Progression-Free Survival Months 2.7 mg/kg ( n=38 ) 3.6 mg/kg ( n=32 ) DoR 6.8 8.0 PFS 2.8 4.3 CERVICAL Complete Response Partial R
Slide 35: CRB-701 potential to differentiate from current standard of care in 2L
CRB-701* ( n=32 ) Tivdak® ( n=253**) IC Chemo 2L+ ( n=249*** ) Mechanism Nectin-4 ADC with MMAE payload (DAR 2) Tissue factor ADC with MMAE payload (DAR 4) Anti-metabolite, cytoskeleton disruption, topoi inhibition etc. Target population 2L 2L 2L Dosing regimen 3.6 mg/kg Q3W 2 mg/kg Q3W various Effi
Slide 36: CRB-913 Daily oral small molecule targeting obesity
CRB-913 Daily oral small molecule targeting obesity
Slide 37: CANYON-1 summary
CANYON-1 summary Enrolled 254 patients across 15 U.S. clinical sites Trial representative of U.S. obesity population BMI average of 37 kg/m2 and 71% of participants female 5% placebo adjusted average weight loss at 12 weeks (60mg) Effect started early and deepened without plateauing All participants
Slide 38: CB1 is a well-characterized receptor in metabolism
Cannabinoid Type-1 (CB1) is a well-characterized receptor (GPCR) in metabolism Note: G protein-coupled receptors (“GPCR”) are the largest and most common family of cell-surface receptors. PAPERS 10K in PubMed on CB1 and metabolism
Slide 39: CRB-913 higher peripheral exposure and lower brain exposure vs. prior CB1s
CRB-913 higher peripheral exposure and lower brain exposure vs. prior CB1s Sources: Corbus murine data Corbus PK modeling based on Phase 1a data CRB-913 ~1/50th Brain:plasma ratio CRB-913 vs. Rimonabant1 ~1/15th Brain level CRB-913 vs. Monlunabant1 Rimonabant Otenabant Ibipinabant Taranabant Monluna
Slide 40: Phase 1b randomized placebo-controlled study design
A 12-week Phase 1b randomized double-blinded placebo-controlled study in adults with obesity Study design All 15 sites located in US Randomization 1:1:1:1 n=254 Placebo QD 12-Week Treatment Phase ( CRB-913 or Placebo QD ) 20mg QD 20mg QD 40mg QD 20mg QD 40mg QD 60mg QD 4-week safety follow-up Weeks
Slide 41: Demographics
Demographics Source: Corbus Pharmaceuticals (data on file) Baseline characteristics CRB-913 20mg ( n=65 ) CRB-913 40mg ( n=61 ) CRB-913 60mg ( n=62 ) Placebo ( n=66 ) Overall ( n=254 ) Female (%) 69.2 72.1 72.6 69.7 70.9 Caucasian (%) 67.7 65.6 75.8 54.5 65.7 Black or African American (%) 30.8 31.1
Slide 42: Dose-dependent weight loss with no plateauing
Dose-dependent weight loss at 12 weeks with no plateauing Efficacy estimand. The LS means, and p-values are the Mixed Model for Repeated Measures (MMRM) with percent change from baseline as the dependent variable; sex, treatment group, visit and treatment group-by-visit interaction as categorical fi
Slide 43: Majority of participants lost weight on CRB-913 compared to placebo
Majority of participants lost weight on CRB-913 compared to placebo Note: Efficacy estimand. Analysis represents weight loss from baseline measured at day 85 for those participants who completed the study. Responder thresholds are cumulative; a participant who achieves a higher percentage of body-we
Slide 44: Comparable weight loss to oral GLP-1s published data
Comparable weight loss to oral GLP-1s published data at 12 weeks Note: Efficacy estimand. These limited observations are derived from separate clinical settings, and do not represent head-to-head comparisons. For orforglipron, early clinical development evaluated a 36 mg capsule formulation; subsequ
Slide 45: Safety and tolerability
CRB-913 20mg (n=65) CRB-913 40mg (n=61) CRB-913 60mg (n=62) Placebo (n=66) All Treatment-Emergent AEs (TEAEs) 39 (60.0%) 45 (73.8%) 45 (72.6%) 28 (42.4%) Severe TEAEs 3 (4.6%) 2 (3.3%) 1 (1.6%) 0 Severe Psych TEAEs 0 0 0 0 Severe GI TEAEs 0 0 0 0 Serious TEAEs 2 (3.1%) 1 (1.6%) 1 (1.6%) 0 All Treatm
Slide 46: Discontinuations due to AEs vs. oral GLP-1 class
Discontinuations due to AEs vs. oral GLP-1 class Note: These limited observations are cross trial comparison derived from separate clinical settings and do not represent head-to-head comparisons. For orforglipron, early clinical development evaluated a 36mg capsule formulation; subsequent bridging e
Slide 47: In-depth analysis of psychiatric safety profile
In-depth analysis of psychiatric safety profile
Slide 48: Suicidality, depression and anxiety mostly mild and transient
Suicidality, depression and anxiety were mostly mild, all transient, and don’t appear dose-related Sources: CANYON-1 data, Ref 1: Lu W, et al. “Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting S
Slide 49: Psychiatric AEs in line with published GLP-1 studies
Suicidality, depression and anxiety were in line with published GLP-1 studies Note: These limited observations are cross trial comparison derived from separate clinical settings and do not represent head-to-head comparisons. Published safety data reflect adverse events reported over study durations
Slide 50: Irritability AE: early, mild and transient
Irritability AE: Irritability occurred early, was always mild + transient did not lead to any discontinuations Source: CANYON-1 data Irritability Placebo 20mg CRB-913 40mg CRB-913 60mg CRB-913 By assigned cohort 0 4 (6.2%) 5 (8.2%) 6 (9.7%) By dose at time of AE 0 7 5 3 All cases were mild and res
Slide 51: Onset of irritability concentrated in the first weeks
Onset of irritability was concentrated in the first 2 weeks Source: CANYON-1 data Irritability First onset of Irritability 7 1–2 2 3–4 2 5–6 1 7–8 9–10 0 11–12 1 13–14 0 15–16 20 mg 40 mg 60 mg Dose at time of event Study week >50% of events occurred by week 4 75% of events occurred by week 6 Treatm
Slide 52: Psych AE discontinuations by dose vs. assigned cohort
Psych AE discontinuations: Analysis of psych AEs discontinuations based on dose vs. assigned cohort (factoring for titration) Psych discontinuations Placebo 20mg CRB-913 40mg CRB-913 60mg CRB-913 By assigned cohort 1 (1.5%) 1 (1.5%) 3 (4.9%) 5 (8.1%) By dose at time of AE 1 3 2 4 1 participant on pl
Slide 53: Psych AEs vs monlunabant
CRB-913 (20/40/60mg) n = 188 Monlunabant1 (10/20/50mg) n = 180 Depression 0%–1.6% 3%–8% Anxiety 3.1%–8.2% 10%–27% Irritability 6.2%–9.7% 10%–17% Insomnia 0%–4.9% 7%–17% AE study discontinuation 1.5%–9.8% 13%–42% Severe psych AE None 2%–7% Unresolved psych AEs None 5%–17% CRB-913 demonstrates favorab
Slide 54: In-depth analysis of GI safety profile
In-depth analysis of GI safety profile
Slide 55: Safety and tolerability: GI AESIs
CRB-913 20mg (n=65) CRB-913 40mg (n=61) CRB-913 60mg (n=62) Placebo (n=66) Vomiting 3 (4.6%) 5 (8.2%) 1 (1.6%) 0 Nausea 10 (15.4%) 16 (26.2%) 14 (22.6%) 3 (4.5%) Constipation 3 (4.6%) 1 (1.6%) 3 (4.8%) 2 (3.0%) Diarrhea 14 (21.5%) 16 (26.2%) 14 (22.6%) 2 (3.0%) Treatment-emergent GI AEs of special i
Slide 56: Diarrhea occurs early, never serious or severe
Diarrhea occurs early, never serious or severe Source: CANYON-1 data. Numbers of patients with events by dose at time event initiation. Participants with events that spanned multiple dose levels are counted in the first dose that triggered the event and not subsequent dose levels. Diarrhea 70% of ev
Slide 57: Potentially improved GI tolerability vs. commercial oral GLP-1s
CRB-9131 (60mg cohort) Oral semaglutide2 (25mg) Orforglipron3 (36mg capsule - Cohort 1) Orforglipron3 (36mg capsule - Cohort 2) Orforglipron4 (FDA Label) Vomiting 1.6% 31% 28% 14% 24% Nausea 22.6% 47% 41% 48% 35% Constipation 4.8% 20% 28% 24% 24% Diarrhea 22.6% 18% 3% 14% 25% Potentially improved GI
Slide 58: Summary and next steps
58 Summary and next steps
Slide 59: Data supports CRB-913 potential as new class of oral non-incretin obesity medicines
Data supports CRB-913 potential as new class of oral non-incretin obesity medicines Note: These limited observations are derived from separate clinical settings, and do not represent head-to-head comparisons Competitive monotherapy & potential to evaluate in combination with GLP-1 Psych AE profile s
Slide 60: CRB-913 moving forward
CRB-913 moving forward Phase 2 Anticipated next steps Present CANYON-1 dataset at ObesityWeek as a late breaker Engage with FDA regarding clinical development plan Initiate Phase 2 monotherapy study in 1H 2027 ("CANYON-2") Evaluate potential combination therapies
Slide 61: Addressable market opportunity for CRB-913 is significant
Addressable market opportunity for CRB-913 is significant Sources: NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. The Lancet 2024
Slide 62: Thank you!
CORBUS PHARMACEUTICALS Thank you!
Corbus Pharmaceuticals Holdings — Investor Presentation (October 2026) on 6ix